血液透析动静脉瘘对冠状动脉旁路移植临床结局的影响
本研究比较了上肢动静脉瘘患者行冠状动脉旁路移植时,原位与游离内乳动脉桥的临床结局。共纳入85例透析依赖患者,原位组48例(56%),游离组37例(44%),随访32.0±38.1个月。两组院内死亡、全因死亡及无主要不良心脏事件生存无显著差异,但原位组心脏相关死亡仅见5例,且同侧原位桥与透析诱发胸痛相关(OR 5.528,95%CI 1.079-28.333,P=0.040)。
要点
- 原位内乳动脉桥与透析诱发胸痛相关(OR 5.528,95%CI 1.079-28.333,P=0.040)。
- 原位非复合、原位复合与游离桥的透析诱发胸痛发生率分别为45.5%、19.4%和5.7%(P=0.009)。
- 两组院内死亡、全因死亡及无主要不良心脏事件生存无显著差异。
核心结论
- 在上肢动静脉瘘患者中,使用同侧原位内乳动脉桥不影响死亡率,但可能增加透析诱发胸痛的发生率,作者认为游离内乳动脉桥可作为替代选择。
研究设计与样本
- 回顾性队列研究,纳入85例透析依赖且存在上肢动静脉瘘、使用内乳动脉桥行冠状动脉旁路移植的患者,分为原位组48例(56%)和游离组37例(44%),随访32.0±38.1个月。
主要发现
- 所有出院患者3年、5年和10年估计总生存率分别为89.5%、81.6%和53%。
- 两组院内死亡、全因死亡及无主要不良心脏事件生存无显著差异,但心脏相关死亡仅见于原位组(n=5)。
- 同侧原位桥与透析诱发胸痛相关(OR 5.528,95%CI 1.079-28.333,P=0.040)。
- 原位非复合桥、原位复合桥和游离桥患者的透析诱发胸痛发生率分别为45.5%、19.4%和5.7%(P=0.009)。
临床怎么用
- 作者认为,对于存在上肢动静脉瘘的患者,游离内乳动脉桥可作为替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study compared clinical outcomes between the use of in situ and free internal thoracic artery grafts in patients with upper extremity arteriovenous fistula who underwent coronary artery bypass. METHODS: We reviewed 85 hemodialysis-dependent patients with upper extremity arteriovenous fistula who underwent coronary artery bypass with internal thoracic artery grafts. The patients were categorized into 2 groups; 48 (56%) with in situ graft ipsilateral to the arteriovenous fistula (group I) and 37 (44%) with free grafts anastomosed to the ascending aorta (group F). The follow-up period was 32.0 ± 38.1 months. RESULTS: The estimated overall survival rates at 3, 5, and 10 years were 89.5%, 81.6%, and 53%, respectively, for all discharged patients. There was no significant difference in in-hospital mortality, all-cause mortality, and freedom from major adverse cardiac events between the groups, although cardiac-related deaths occurred only in group I (n = 5). Ipsilateral in situ grafts were associated with hemodialysis-induced chest pain (odds ratio, 5.528; 95% confidence interval, 1.079 to 28.333; p = 0.040). The incidence of dialysis-induced chest pain in patients with in situ noncomposite, in situ composite, and free grafts was 45.5%, 19.4%, and 5.7%, respectively (p = 0.009). CONCLUSIONS: Mortality was not influenced by using the internal thoracic artery as an ipsilateral in situ graft in patients with upper extremity arteriovenous fistula. However, there was a risk of increased incidence of hemodialysis-induced chest pain that is most likely related to coronary steal. A free internal thoracic artery graft would be an alternative option in these patients.
引用
- Shim H, Jeong DS, Kim WS, et al. Impact of Arteriovenous Fistula for Hemodialysis on Clinical Outcomes of Coronary Artery Bypass. Ann Thorac Surg. 2018. PMID: 30118708. doi:10.1016/j.athoracsur.2018.06.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。